Contraceptive Options for Women with Headache Disease

  • Deborah Bartz
  • M. Angela O’Neal
  • Andrea G. Edlow


This chapter addresses the effects of hormonal contraceptives on headache, in particular, migraine. The definition, incidence, and prevalence for migraine with and without aura are reviewed. The discussion explores the stroke risk associated with both hormonal contraception and migraine and also includes the special contraceptive concerns regarding estrogen withdrawal headache, menstrual migraine, and idiopathic intracranial hypertension. A case-based approach is used to allow practitioners an understanding of how to implement best practice recommendations, especially the selection of appropriate candidates for initiation of hormone-containing contraceptives, and decision-making about method continuation among women complaining of headache while taking hormonal contraceptives.


Ischemic Stroke Migraine With Aura Ethinyl Estradiol Idiopathic Intracranial Hypertension Migraine Without Aura 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Stewart WF, Wood C, Reed ML, Roy J, Lipton RB, AMPP Advisory Group. Cumulative lifetime migraine incidence in women and men. Cephalalgia. 2008; 28:1170–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Finer LB, Frohwirth LF, Dauphinee LA, Singh S, Moore AM. Reasons U.S. women have abortions: quantitative and qualitative perspectives. Perspect Sex Reprod Health. 2005;37:110–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179:577–82.PubMedCrossRefGoogle Scholar
  4. 4.
    Rosenberg MJ, Waugh MS, Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. J Reprod Med. 1995;40:355–60.PubMedGoogle Scholar
  5. 5.
    Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–9.PubMedCrossRefGoogle Scholar
  6. 6.
    MacGregor EA. Migraine and use of combined hormonal contraceptives: a clinical review. J Fam Plann Reprod Health Care. 2007;33:159–69.PubMedCrossRefGoogle Scholar
  7. 7.
    Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd ed. Cephalalgia. 2004;24 suppl 1:9–160.Google Scholar
  8. 8.
    Charles A. Advances in the basic and clinical science of migraine. Ann Neurol. 2009;65:491–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain. 1996; 119(Pt 2):355–61.PubMedCrossRefGoogle Scholar
  10. 10.
    Merikangas KR, Fenton BT, Cheng SH, Stolar MJ, Risch N. Association between migraine and stroke in a large-scale epidemiological study of the United States. Arch Neurol. 1997;54:362–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Chang CL, Donaghy M, Poulter N, The World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Migraine and stroke in young women: case–control study. BMJ. 1999;318:13–8.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    MacClellan LR, Giles W, Cole J, Wozniak M, Stern B, Mitchell BD, et al. Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke. 2007;38:2438–45.PubMedCrossRefGoogle Scholar
  13. 13.
    Kurth T, Slomke MA, Kase CS, Cook NR, Lee IM, Gaziano JM, et al. Migraine, headache, and the risk of stroke in women: a prospective study. Neurology. 2005;64:1020–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. JAMA. 2006;296: 283–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ. 2005;330:63–6.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Henrich JB, Horwitz RI. A controlled study of ischemic stroke risk in migraine patients. J Clin Epidemiol. 1989;42:773–80.PubMedCrossRefGoogle Scholar
  17. 17.
    Carolei A, Marini C, De Matteis G, The Italian National Research Council Study Group on Stroke in the Young . History of migraine and risk of cerebral ischaemia in young adults. Lancet. 1996;347:1503–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Tzourio C, Iglesias S, Hubert JB, Visy JM, Alpérovitch A, Tehindrazanarivelo A, et al. Migraine and risk of ischaemic stroke: a case–control study. BMJ. 1993; 307:289–92.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Tzourio C, Tehindrazanarivelo A, Iglésias S, Alpérovitch A, Chedru F, d’Anglejan-Chatillon J, et al. Case–control study of migraine and risk of ischaemic stroke in young women. BMJ. 1995;310: 830–3.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Bousser MG, Conard J, Kittner S, de Lignières B, MacGregor EA, Massiou H, The International Headache Society Task Force on Combined Oral Contraceptives & Hormone Replacement Therapy, et al. Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. Cephalalgia. 2000;20:155–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low-dose oral contraceptives. N Engl J Med. 1996;335:8–15.PubMedCrossRefGoogle Scholar
  22. 22.
    Stang PE, Carson AP, Rose KM, Mo J, Ephross SA, Shahar E, et al. Headache, cerebrovascular symptoms, and stroke: the Atherosclerosis Risk in Communities Study. Neurology. 2005;64:1573–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Lidegaard Ø. Oral contraception and risk of a cerebral thromboembolic attack: results of a case–control study. BMJ. 1993;306:956–63.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Lidegaard Ø, Kreiner S. Contraceptives and cerebral thrombosis: a five-year national case control study. Contraception. 2002;65:197–205.PubMedCrossRefGoogle Scholar
  25. 25.
    Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA. 2000;284:72–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Heinemann LA, Lewis MA, Spitzer WO, Thorogood M, Guggenmoos-Holzmann I, Bruppacher R, Transnational Research Group on Oral Contraceptives and the Health of Young Women. Thromboembolic stroke in young women. A European case–control study on oral contraceptives. Contraception. 1998;57:29–37.PubMedCrossRefGoogle Scholar
  27. 27.
    WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case–control study. Lancet. 1996;348:498–505.CrossRefGoogle Scholar
  28. 28.
    Lidegaard O, Lokkegaard E, Jenson A, Skovlund C, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257–66.PubMedCrossRefGoogle Scholar
  29. 29.
    World Health Organization. Medical eligibility criteria for contraceptive use. 4th ed. Geneva: World Health Organization; 2009.Google Scholar
  30. 30.
    Donaghy M, Chang CL, Poulter N, on behalf of the European Collaborators of the World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. J Neurol Neurosurg Psychiatry. 2002; 73:747–50.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    MacGregor EA. Menstrual migraine: a clinical review. J Fam Plann Reprod Health Care. 2007;33: 36–47.PubMedCrossRefGoogle Scholar
  32. 32.
    World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case–control study. Contraception. 1998;57:315–24.CrossRefGoogle Scholar
  33. 33.
    Schwartz SM, Petitti DB, Siscovick DS, Longstreth Jr WT, Sidney S, Raghunathan TE, et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke. 1998; 29:2277–84.PubMedCrossRefGoogle Scholar
  34. 34.
    Lidegaard Ø. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol. 1995;102: 153–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    ACOG Committee on Practice Bulletins-Gynecology. Practice Bulletin ACOG. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107:1453–72.CrossRefGoogle Scholar
  37. 37.
    Duncan J, Corbett J, Wall M. The incidence of pseudotumor cerebri population studies in Iowa and Louisiana. Arch Neurol. 1988;45(8):875–7.CrossRefGoogle Scholar
  38. 38.
    Bousse V, Bruce B, Newman N. Update on the pathophysiology of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry. 2012;83:488–94.CrossRefGoogle Scholar
  39. 39.
    Robinson JA, Burke AE. Obesity and hormonal contraceptive efficacy. Womens Health. 2013;9(5):453–66.Google Scholar
  40. 40.
    Edelman A, Jensen J. Obesity and hormonal contraception: safety and efficacy. Semin Reprod Med. 2012;30(06):479–85.PubMedCrossRefGoogle Scholar
  41. 41.
    Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Napp G. Migraine with aura and reproductive life events: a case control study. Cephalalgia. 2000; 20:701–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Loder EW, Buse DC, Golub JR. Headache and combination estrogen-progestin oral contraceptives: integrating evidence, guidelines, and clinical practice. Headache. 2005;45:224–31.PubMedCrossRefGoogle Scholar
  43. 43.
    Larsson-Cohn U, Lundberg PO. Headache and treatment with oral contraceptives. Acta Neurol Scand. 1970;46:267–78.PubMedCrossRefGoogle Scholar
  44. 44.
    Loder EW, Buse DC, Golub JR. Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. Am J Obstet Gynecol. 2005;193(3 Pt 1):636–49.PubMedCrossRefGoogle Scholar
  45. 45.
    Somerville BW, Carey HM. The use of continuous progestogen contraception in the treatment of migraine. Med J Aust. 1970;1:1043–5.PubMedGoogle Scholar
  46. 46.
    Davies P, Fursdon-Davies C, Rees MC. Progestogens for menstrual migraine. J Br Menopause Soc. 2003; 9:134.PubMedGoogle Scholar
  47. 47.
    Croxatto HB, Mäkaräinen L. The pharmacodynamics and efficacy of Implanon. An overview of the data. Contraception. 1998;58:91S–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Fotherby K. Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel. Contraception. 1995;51:3–12.PubMedCrossRefGoogle Scholar
  49. 49.
    MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006;67:2154–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Silberstein SD. The role of sex hormones in headache. Neurology. 1992;42(3 suppl2):37–42.PubMedGoogle Scholar
  52. 52.
    Silberstein S. Headache and female hormones: what you need to know. Curr Opin Neurol. 2001;14: 323–33.PubMedCrossRefGoogle Scholar
  53. 53.
    MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology. 2004;63:351–3.PubMedCrossRefGoogle Scholar
  54. 54.
    MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover stud. Neurology. 2006;67:2159–63.PubMedCrossRefGoogle Scholar
  55. 55.
    MacGregor EA, Hackshaw A. Prevention of migraine in the pill-free interval of combined oral contraceptives: a double-blind, placebo-controlled pilot study using natural oestrogen supplements. J Fam Plann Reprod Health Care. 2002;28:27–31.PubMedCrossRefGoogle Scholar
  56. 56.
    Edelman A, Gallo MF, Nichols MD, Jensen JT, Schulz KF, Grimes DA. Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum Reprod. 2006;21:573–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Johannes CB, Linet MS, Stewart WF, Celentano DD, Lipton RB, Szklo M. Relationship of headache to phase of the menstrual cycle among young women: a daily diary study. Neurology. 1995;45:1076–82.PubMedCrossRefGoogle Scholar
  58. 58.
    Facchinetti F, Bonellie G, Kangasniemi P, Pascual J, Shuaib A, The Sumatriptan Menstrual Migraine Study Group. The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. Obstet Gynecol. 1995;86:911–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet Gynecol. 1993;82:769–72.PubMedGoogle Scholar
  60. 60.
    Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache. 1990;30:705–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Ashkenazi A, Silberstein S. Menstrual migraine: a review of hormonal causes, prophylaxis and treatment. Expert Opin Pharmacother. 2007;8: 1605–13.PubMedCrossRefGoogle Scholar
  62. 62.
    Al-Waili NS. Treatment of menstrual migraine with prostaglandin synthesis inhibitor mefenamic acid: double-blind study with placebo. Eur J Med Res. 2000;5:176–82.PubMedGoogle Scholar
  63. 63.
    Mannix LK, Martin VT, Cady RK, Diamond ML, Lener SE, White JD, et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol. 2009;114:106–13.PubMedCrossRefGoogle Scholar
  64. 64.
    Massiou H, MacGregor EA. Evolution and treatment of migraine with oral contraceptives. Cephalalgia. 2000;20:170–4.PubMedCrossRefGoogle Scholar
  65. 65.
    Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology. 2008; 70:1555–63.PubMedCrossRefGoogle Scholar
  66. 66.
    de Lignières B, Vincens M, Mauvais-Jarvis P, Mas JL, Touboul PJ, Bousser MG. Prevention of menstrual migraine by percutaneous oestradiol. Br Med J (Clin Res Ed). 1986;293:1540.CrossRefGoogle Scholar
  67. 67.
    Dennerstein L, Morse C, Burrows G, Oats J, Brown J, Smith M. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol. 1988;2: 113–20.PubMedCrossRefGoogle Scholar
  68. 68.
    Menon R, Bushnell CD. Headache and pregnancy. Neurologist. 2008;14:108–19.PubMedCrossRefGoogle Scholar
  69. 69.
    Contag SA, Mertz HL, Bushnell CD. Migraine during pregnancy: is it more than a headache? Nat Rev Neurol. 2009;5:449–56.PubMedCrossRefGoogle Scholar
  70. 70.
    Kelman L. Women’s issues of migraine in tertiary care. Headache. 2004;44:2–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Scharff L, Marcus DA, Turk DC. Headache during pregnancy and in the postpartum: a prospective study. Headache. 1997;37:203–10.PubMedCrossRefGoogle Scholar
  72. 72.
    Aegidius K, Zwart JA, Hagen K, Stovner L. The effect of pregnancy and parity on headache prevalence: the Head-HUNT study. Headache. 2009;49:851–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Bialer M, Doose DR, Murthy B, Curtin C, Curtin C, Wang SS, Twyman RE, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004; 43(12):763–80.PubMedCrossRefGoogle Scholar
  74. 74.
    Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med. 2008;359:2025–33.PubMedCrossRefGoogle Scholar
  75. 75.
    Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet. 1999;353:1258–65.PubMedCrossRefGoogle Scholar
  76. 76.
    Kujovich JL. Hormones and pregnancy: thromboembolic risks for women. Br J Haematol. 2004;126: 443–54.PubMedCrossRefGoogle Scholar
  77. 77.
    Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton 3rd LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143:697–706.PubMedCrossRefGoogle Scholar
  78. 78.
    NIH Consensus Development. Prevention of venous thrombosis and pulmonary embolism. JAMA. 1986; 256:744–9.CrossRefGoogle Scholar
  79. 79.
    Kittner SJ, Stern BJ, Feeser BR, Hebel R, Nagey DA, Buchholz DW, et al. Pregnancy and the risk of stroke. N Engl J Med. 1996;335:768–74.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Deborah Bartz
    • 1
  • M. Angela O’Neal
    • 2
  • Andrea G. Edlow
    • 3
  1. 1.Department of Obstetrics, Gynecology, and Reproductive BiologyHarvard Medical School, Brigham and Women’s HospitalBostonUSA
  2. 2.Department of NeurologyBrigham and Women’s HospitalBostonUSA
  3. 3.Division of Maternal-Fetal Medicine, Department of Obstetrics and GynecologyTufts Medical CenterBostonUSA

Personalised recommendations